We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-0.58%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$96.1M
AUM Growth
+$44.5M
Cap. Flow
+$50.6M
Cap. Flow %
52.63%
Top 10 Hldgs %
88.73%
Holding
19
New
6
Increased
3
Reduced
7
Closed
2

Top Buys

1
LGND icon
Ligand Pharmaceuticals
LGND
+$25.1M
2
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
+$8.86M
3
SBBP
Strongbridge Biopharma plc.
SBBP
+$6.49M
4
GYRE icon
Gyre Therapeutics
GYRE
+$4.51M
5
ATRS
Antares Pharma, Inc.
ATRS
+$3.34M

Top Sells

1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$1.8M
2
AVTX icon
Avalo Therapeutics
AVTX
+$1.17M
3
ADMS
Adamas Pharmaceuticals
ADMS
+$388K
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$383K
5
CPIX icon
Cumberland Pharmaceuticals
CPIX
+$286K

Sector Composition

1 Healthcare 97.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LGND icon
1
Ligand Pharmaceuticals
LGND
$6.08B
$30.6M 31.88%
515,365
+367,237
+248% +$25.1M
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$13.3M 13.86%
2,362,240
-377,401
-14% -$1.8M
AMYT
3
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$9.46M 9.84%
+765,236
New +$8.86M
CTIC
4
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$8.1M 8.43%
3,768,597
-299,594
-7% -$383K
GYRE icon
5
Gyre Therapeutics
GYRE
$675M
$6.07M 6.31%
188,188
+115,183
+158% +$4.51M
DMAC icon
6
DiaMedica Therapeutics
DMAC
$393M
$4.86M 5.06%
1,146,470
+478,040
+72% +$2.53M
SBBP
7
DELISTED
Strongbridge Biopharma plc.
SBBP
$4.04M 4.2%
+1,924,956
New +$6.49M
ATRS
8
DELISTED
Antares Pharma, Inc.
ATRS
$3.25M 3.39%
+1,205,501
New +$3.34M
XOMA
9
DELISTED
Xoma
XOMA
$2.83M 2.94%
150,213
– –
ADMS
10
DELISTED
Adamas Pharmaceuticals
ADMS
$2.71M 2.82%
657,467
-100,237
-13% -$388K
APEN
11
DELISTED
Apollo Endosurgery, Inc.
APEN
$2.41M 2.51%
1,425,435
-22,330
-2% -$33.7K
NEOS
12
DELISTED
Neos Therapeutics, Inc
NEOS
$2.33M 2.42%
4,384,199
-62,827
-1% -$42.7K
CPIX icon
13
Cumberland Pharmaceuticals
CPIX
$102M
$1.89M 1.97%
589,497
-87,095
-13% -$286K
CHMA
14
DELISTED
Chiasma, Inc. Common Stock
CHMA
$1.5M 1.57%
+350,000
New +$1.68M
AFMD
15
DELISTED
Affimed
AFMD
$1.21M 1.26%
+35,767
New +$1.35M
IDXG
16
DELISTED
Interpace Biosciences, Inc. Common Stock
IDXG
$880K 0.92%
+284,730
New +$1.29M
BIOR
17
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
$614K 0.64%
272
-113
-29% -$256K
AVTX icon
18
Avalo Therapeutics
AVTX
$1.02B
– –
-156
Closed -$1.17M
FRTX
19
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
– –
-3,261
Closed -$147K

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Stonepine Capital Management held 19 positions worth $96.1M, up 86% from $51.6M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Stonepine Capital Management deployed $50.6M of net new capital in Q3 2020, opening 6 new positions and adding to 3 existing holdings. Its largest new stake was Amryt Pharma plc American Depositary Shares: 765,236 shares worth $9.46M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was IVERIC bio, Inc. Common Stock, an estimated $1.8M trimmed.

  • Stonepine Capital Management's largest Q3 2020 buy was Amryt Pharma plc American Depositary Shares: 765,236 shares worth $9.46M.
  • Stonepine Capital Management added most to Ligand Pharmaceuticals in Q3 2020, an estimated $25.1M increase.
  • Stonepine Capital Management's biggest Q3 2020 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $1.8M.
  • Stonepine Capital Management fully exited Avalo Therapeutics in Q3 2020, selling an estimated $1.17M.
  • Stonepine Capital Management's ten largest holdings make up 89% of its $96.1M portfolio in Q3 2020.
  • Stonepine Capital Management opened 6 new positions and closed 2 in Q3 2020.
  • Stonepine Capital Management's portfolio value rose 86% quarter-over-quarter to $96.1M.

Based on Stonepine Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.